31. Serious and Non-serious Adverse Event Monitoring : Adverse events should be documented and recorded at each visit using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC AE) version 5.0. Participants must be followed for AEs for 6 months after the last study treatment administration or until all drug related toxicities have resolved, whichever is later; or earlier than 6 months should the participant commence another anticancer therapy in the meantime. The time period for actively eliciting and collecting AEs and SAEs (“active collection period”) for each participant begins from the time the participant provides informed consent through and including 6 months after the last study treatment administration or until all drug related toxicities have resolved, whichever is later. If the participant begins a CCI CCI CCI PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 21Protocol Activity Screen 1 (£28 days)Treat ment Period Post Treat ment Cycle 1 Cycle 2 End of Treat ment 33Follow -Up (Months after EOT visit)Survival Follow -up35 Study Day Day 1Day 8Day 15Day 22Day 29Day 43Day 57Day 71Day 85Day 113Month 134Month 2 Month 4 Month 6 Post 6 -Month Follow -up Cycle Day Day 1Da y 29Day 57Da y 85Day 9928 to 35 daysEvery 3 Months Visit Window (Days) *±1 ±2 ±2 ±2 ±4 ±2 ±4 ±2 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±10 new anticancer therapy, the period for recording non-serious AEs on the CRF ends at the time the new treatment is started. However, any SAEs occurring during the active collection period must still be reported to Pfizer Safety and recorded on the CRF, irrespective of any intervening treatment. 32. Concom itant Treatments : All concomitant medications and non -drug supportive interventions should be recorded in the CRF. 33. End of Treatment Visit: The End of treatment v isit will be completed at the time point when a decision is made to discontinue study treatment. This can occur during Cycles 1 or 2 or during the Maintenance Treatment Phase of the study. Obtain these assessments if not completed in the past two weeks ( past 6 weeks for tumor assessments). 34. Follow -up: At least 28 days, and no more than 35 days after discontinuation of study treatment, participants will return to complete the required assessments. Participants will then return at Month 2, Month 4 and Month 6 to complete the required assessments. 35. Survival: After treatment discontinuation, participant survival status will be collected every 3 months until death, participant refusa l, or lost to follow -up (telephone contact acceptable). PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 22SCHEDULE OF ACTIVITIES FOR MAINTENANCE TREATMENT PERIOD FOR DOSE ESCALATION (PART 1) Protocol Activity Maintenance Treatment Period* Study Month ** Month 9 Month 10Month 11Month 12Month 13Month 14Month 15Month 16Month 17Month 18 Month 19Month 20Month 21Month 22 and every month thereafte r Visit Window (Days) ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 Abbreviated physical examination1XXXXXX X1 W e i g h t XXXXXXXXXXXXX X1 Vital signs2XXXXXXXXXXXXX X1 Performance status3XXXXXXXXXXXXX X1 Laboratory Hematolog y4XXXXXX X1 Blood Chemistr y5XXXXXX X1 Coagulation6XXX X11 Cardiac Troponin-I (cTnI)7XX Urinalysis8XXX X11 Pregnancy Test or FSH Level (Serum)9XXXXXXXXXXXXXX Contraception Check10XXXXXXXXXXXXXX (12 lead) ECG12XX X * Study Treatment pDNA Administration13XXXXXX X1 Tremelimumab administration for cohorts assigned to receive tremelimumab13XXXXXX X1 Sasanlimab administration for cohorts assigned to receive sasanlimab13XXXXXXXXXXXXXX Tumor Assessment CT scan, MRI scan or bone scan 14X14 Other Samplings PK and Tremelimumab ADA X X X X11 PK and Sasanlimab ADA X X X X11 CCI PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 23Protocol Activity Maintenance Treatment Period* Study Month ** Month 9 Month 10Month 11Month 12Month 13Month 14Month 15Month 16Month 17Month 18 Month 19Month 20Month 21Month 22 and every month thereafte r Visit Window (Days) ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 Other clinical assessments Serious and non-serious adverse event monitoring18XXXXXXXXXXXXXX Concomitant medications and non-drug supportive interventions 19XXXXXXXXXXXXXX Abbreviations: Ĭ= ongoing; ADA = anti-drug antibodies; AdC68= Adenovirus; AE = adverse events; CT = computed tomography; ECG = electrocardiogra m;EOT = End of Treatment; MRI = magnetic resonance imaging; PBMC = peripheral blood mononuclear cell; pDNA= plasmid deoxyribonucleic acid; SC = Subcutaneous(ly) * When a decision is made to discontinue study treatment during the Maintenance Treatment Period, the End of Treatment visit as sessments should be performed. The participant will then enter the Post Treatment Period of the study. ** Study visit is based on completion of two cycles in the treatment period. Visit window for the first maintenance treatment visit is to be calculated based on the Cycle 2 Day 85 dosing date. The first dose in the maintenance period should occur 28 days after the C2D85 dosing date. A month is defined as 28 days. 1.